Boehringer Ingelheim acquires Nerio Therapeutics for new immune checkpoint inhibitor

On July 29, 2024, Boehringer Ingelheim, based in INGOELHEIM, Germany, and LA JOLLA, CA, USA, marked a major advancement in its immuno-oncology pipeline by acquiring Nerio Therapeutics Inc. The deal, valued at up to USD 1.3 billion, aims to integrate an innovative preclinical program into Boehringer Ingelheim's portfolio. This strategic acquisition aims to enhance the company’s mission of improving cancer patient outcomes through advanced treatments.

Nerio Therapeutics specializes in small molecules that inhibit the protein tyrosine phosphatases N1 and N2 (PTPN1 and PTPN2), which function as immune checkpoints. By inhibiting these proteins, Nerio’s compounds can potentially activate the immune system to more effectively target and destroy cancer cells.

Immune checkpoint blockade therapies have revolutionized cancer treatment, yet they do not benefit all patients. Boehringer Ingelheim recognizes this limitation and is dedicated to expanding the advantages of immuno-oncology to a broader range of patients. The company is focused on developing a comprehensive suite of therapies that utilize immune checkpoint blockades to enhance the immune system's ability to combat cancer. Nerio's small molecule inhibitors are expected to become a critical component of this portfolio, both as standalone therapies and in combination with other treatments that Boehringer Ingelheim is currently developing.

Paola Casarosa, a member of Boehringer Ingelheim’s Board of Managing Directors and head of the Innovation Unit, emphasized the significance of acquiring Nerio’s novel checkpoint inhibitors. According to Casarosa, these inhibitors open up numerous exciting possibilities for new cancer treatment combinations, bringing the company closer to its goal of transforming the lives of cancer patients.

Sanford Madigan, partner at Avalon BioVentures, L.P., and co-founder and CEO of Nerio Therapeutics, echoed this enthusiasm. Madigan highlighted the superior drug-like properties of Nerio’s PTPN1/N2 inhibitors and described them as a first-in-class opportunity. He expressed excitement about integrating these compounds into Boehringer Ingelheim’s pipeline and praised the company’s commitment to fully realizing the potential of these unique cancer-fighting compounds.

This acquisition signifies a bold move toward revolutionizing cancer treatment. It strengthens Boehringer Ingelheim’s oncology pipeline, which includes both cancer cell-directed and immuno-oncology investigational therapies. These smart combinations offer the potential for significant benefits for cancer patients.

Boehringer Ingelheim is a leading biopharmaceutical company engaged in human and animal health. With a strong focus on research and development, the company is dedicated to creating innovative therapies to address areas of high unmet medical need. Since its foundation in 1885, Boehringer Ingelheim has remained independent and committed to sustainability throughout its operations. The company employs over 53,500 people and serves more than 130 markets worldwide.

Nerio Therapeutics, a drug discovery and development company, focuses on targeting phosphatases, a challenging yet potentially valuable class of therapeutic proteins. Nerio has developed potent and selective PTPN2/N1 inhibitors with excellent drug-like properties. These inhibitors enhance immune function and sensitize tumors to pro-inflammatory signals, promoting strong anti-tumor activity. Founded by Avalon Ventures and financially supported by a syndicate of investors, Nerio has leveraged Avalon BioVentures’ expertise in early-stage drug development to achieve its innovative breakthroughs.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!